Of note, the anti-PD-L1 agent atezolizumab plus bevacizumab in combination with carboplatin and paclitaxel has already received FDA approval for the treatment of metastatic non-squamous NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberration based on the IMpower 150 results [48,49]. Here, ALK is linked to non-small cell lung carcinoma.